Determination of Tafamidis Plasma Concentrations in Amyloidosis Patients with Glu89Gln Mutation by HPLC-UV Detection.

Type of publication: Academic publication
Disease: Neuromuscular disease,

Authors:

Miglena Smerikarova, Stanislav Bozhanov, Vania Maslarska, Ivailo Tournev


Present study describes a high-performance liquid chromatography method for the determination of the potent kinetic stabilizer—Tafamidis in human plasma. It was approved for medical use in European Union in 2011. Ultra violet (UV) detection mode and isocratic elution of the mobile phase were set and made the analytical procedure fast and widely applicable. Chromatographic determination was performed on a Purospher® RP-18 column. The mobile phase consisted of 0.1% trifluoroacetic acid in water and acetonitrile in the ratio 42:58 v/v and the flow rate was 1.0 ml/min. All analyses were carried at a room temperature and the detector was set at 280 nm. Calibration curve over a range of 1.00–10.00 μM was constructed for the purposes of linearity method validation. The specificity and effectiveness of the developed method made it suitable for observation of patients’ plasma Tafamidis concentration with time and drug therapy monitoring.


Published: 11 December 2021
Journal: Journal of chromatographic science, volume bmab132

Link: doi.org/10.1093/chromsci/bmab132

Link: Read here

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern